SHANGHAI, China, Dec. 5 /PRNewswire/ -- Representatives from over 40 Shanghai area hospitals, more than double the expected attendance, took part in the first annual Cinpathogen Hematology Conference at Shanghai's Equatorial Hotel. The conference, hosted by Cinpathogen Inc. and chaired by Professor Lin Guowei, Director of the Shanghai Clinical Epidemiology Institute, covered current developments in clinical laboratory medicine and shared valuable findings from the Shanghai Health Study.
"The level of interest in the conference was far beyond what we expected," said Dr. Richard Irons, Laboratory Director and Cinpathogen CEO. "It demonstrates the growing demand for high-quality healthcare delivery and research in China."
The event included presentations by Western and Chinese hematologists and pathologists on recent developments and research findings in the field of clinical diagnosis, hematology, toxicology, and pathology. The research presented was the result of the Shanghai Health Study, a 5-year-long clinical study of Chinese patients with hematopoietic disease, led by Cinpathogen Inc. through its partnership with Fudan University and the extensive cooperation of leading hospitals in Shanghai. Cinpathogen's well-established research relationships have allowed company doctors and scientists to diagnose, collect and characterize over 2000 cases of hematopoietic and lymphoid disease over the last 4 years, resulting in a dozen peer-reviewed publications and one of the world's largest tissue banks dedicated to diseases of the blood and immune system.
Professor Ouyang Renrong, former chairman of both the Chinese
Hematology Society and the Shanghai Hematology Society, applauded the
accomplishment. "The Shanghai Health Study is one-of-its-kind in China and
probably in the world. It is strong evidence of how science can make
outstanding contributions to society through an integrated, big sampling
approach. Had each hospital in Shanghai focused o
|SOURCE Cinpathogen Inc.|
Copyright©2007 PR Newswire.
All rights reserved